MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress

被引：0
|
作者：
Catenacci, D. V. [1 ]
Strickler, J. H. [2 ]
Shitara, K. [3 ]
Nakamura, Y. [3 ]
Janjigian, Y. Y. [4 ]
Barzi, A. [5 ]
Bekaii-Saab, T. [6 ]
Lenz, H. J. [7 ]
Chung, H. C. [8 ]
Tabernero, J. [9 ]
Yoshino, T. [3 ]
Siena, S. [10 ]
Mayor, J. G. [11 ]
Palanca-Wessels, M. C. [11 ]
Xie, D. [12 ]
Marshall, J. L. [13 ,14 ]
机构：
[1] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA
[2] Duke Univ, Med Ctr, Med, Durham, NC USA
[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[5] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[6] Mayo Clin, Oncol Med, Scottsdale, AZ USA
[7] USC Norris Comprehens Canc Ctr, Dept Med Oncol, Los Angeles, CA USA
[8] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Med Oncol Dept, Seoul, South Korea
[9] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain
[10] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy
[11] Univ Milan, Milan, Italy
[12] Seagen Inc, Clin Dev Dept, Seattle, WA USA
[13] Seagen Inc, Biostat, Bothell, WA USA
[14] Georgetown Univ, Div Hematol Oncol, Washington, DC USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1434TiP
引用
收藏
页码：S1071 / S1072
页数：2
相关论文
共 50 条
  • [1] MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in Progress
    Strickler, John H.
    Nakamura, Yoshiaki
    Yoshino, Takayuki
    Catenacci, Daniel V. T.
    Janjigian, Yelena Y.
    Barzi, Afsaneh
    Bekaii-Saab, Tanios S.
    Lenz, Heinz-Josef
    Lee, Jeeyun
    Van Cutsem, Eric
    Chung, Hyun Cheol
    Alsina, Maria
    Siena, Salvatore
    Mayor, Joal Garrido
    Palanca-Wessels, Maria Corinna
    Feng Wentao
    Marshall, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Tabernero, J.
    Strickler, J.
    Nakamura, Y.
    Shitara, K.
    Janjigian, Y.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H.
    Yoshino, T.
    Siena, S.
    Garrido-Mayor, J.
    Ubowski, M.
    Xie, D.
    Marshall, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S305 - S306
  • [3] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Strickler, J.
    Nakamura, Y.
    Shitara, K.
    Catenacci, D.
    Janjigian, Y.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H.
    Lee, J.
    Van Cutsem, E.
    Chung, H.
    Tabernero, J.
    Yoshino, T.
    Siena, S.
    Garrido-Mayor, J.
    Palanca-Wessels, M.
    Xie, D.
    Marshall, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S159 - S159
  • [4] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress
    Catenacci, Daniel V. T.
    Strickler, John H.
    Nakamura, Yoshiaki
    Shitara, Kohei
    Janjigian, Yelena Y.
    Barzi, Afsaneh
    Bekaii-Saab, Tanios S.
    Lenz, Heinz-Josef
    Chung, Hyun Cheol Cheol
    Tabernero, Josep
    Yoshino, Takayuki
    Siena, Salvatore
    Mayor, Joal Garrido
    Palanca-Wessels, Maria Corinna
    Xie, Diqiong
    Marshall, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [5] Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+gastroesophageal cancer (GEC)
    Tehfe, M.
    Lee, J.
    Rha, S. Y.
    Nakamura, Y.
    Tabernero, J.
    Shitara, K.
    Oh, D-Y.
    Eads, J.
    Marshall, J.
    Wainberg, Z. A.
    Lee, K-W.
    Kang, Y-K.
    Liao, C-Y.
    Oh, S. Y.
    Yeh, K-H.
    Richards, D.
    Ubowski, M. M.
    Zhao, K.
    Bhaumik, S.
    Strickler, J. H.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S857 - S858
  • [6] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Cecchini, Michael
    Cleary, James M.
    Shyr, Yu
    Chao, Joseph
    Uboha, Nataliya
    Cho, May
    Shields, Anthony
    Pant, Shubham
    Goff, Laura
    Spencer, Kristen
    Kim, Edward
    Stein, Stacey
    Kortmansky, Jeremy S.
    Canosa, Sandra
    Sklar, Jeffrey
    Swisher, Elizabeth M.
    Radke, Marc
    Ivy, Percy
    Boerner, Scott
    Durecki, Diane E.
    Hsu, Chih-Yuan
    Lorusso, Patricia
    Lacy, Jill
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 476 - 482
  • [7] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Michael Cecchini
    James M. Cleary
    Yu Shyr
    Joseph Chao
    Nataliya Uboha
    May Cho
    Anthony Shields
    Shubham Pant
    Laura Goff
    Kristen Spencer
    Edward Kim
    Stacey Stein
    Jeremy S. Kortmansky
    Sandra Canosa
    Jeffrey Sklar
    Elizabeth M. Swisher
    Marc Radke
    Percy Ivy
    Scott Boerner
    Diane E. Durecki
    Chih-Yuan Hsu
    Patricia LoRusso
    Jill Lacy
    [J]. British Journal of Cancer, 2024, 130 : 476 - 482
  • [8] Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
    Al-Batran, S. -E.
    Van Cutsem, E.
    Oh, S. C.
    Bodoky, G.
    Shimada, Y.
    Hironaka, S.
    Sugimoto, N.
    Lipatov, O. N.
    Kim, T. -Y.
    Cunningham, D.
    Rougier, P.
    Muro, K.
    Liepa, A. M.
    Chandrawansa, K.
    Emig, M.
    Ohtsu, A.
    Wilke, H.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 673 - 679
  • [9] Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).
    Rha, Sun Young
    Kim, Chang Gon
    Jung, Minkyu
    Kim, Hyo Song
    Lee, Choong-kun
    Jeung, Hei-Cheul
    Koo, Dong-Hoe
    Bae, Woo Kyun
    Zang, Dae Young
    Kim, Hyunki
    Chung, Hyun Cheol Cheol
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
    Stinchcombe, Tom
    Monk, Bradley J.
    Okines, Alicia Frances Clare
    Pohlmann, Paula R.
    Yu, Evan Y.
    Bekaii-Saab, Tanios S.
    Nakamura, Yoshiaki
    O'Malley, David M.
    Kang, Vicky
    Walker, Luke N.
    Reck, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345